Management of Hepatitis C Virus and Hepatitis B Virus Infection in the Setting of Kidney Disease

Sharma, Purva; Sawtell, Rani; Wang, Qiyu; Sise, Meghan E.

doi:10.1053/j.akdh.2023.04.003

Cited by 3 publications

(7 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic infection with HCV and HBV can lead to glomerular disease through the production and deposition of immune complexes in the glomerulus and podocyte dysregulation. 44 Chronic HCV infection usually causes mixed cryoglobulinemia, a pattern of polyclonal IgG and monoclonal IgM, which can cause a cryoglobulinemic glomerulonephritis. 44 HCV infection can course with other glomerular diseases, like non-cryoglobulinemic MPGN, MN, FSGS, IgAN, and polyarteritis nodosa (PAN), and these glomerulopathies can also occur in kidney allografts.…”

Section: Viral Glomerulopathiesmentioning

confidence: 99%

“… 44 Chronic HCV infection usually causes mixed cryoglobulinemia, a pattern of polyclonal IgG and monoclonal IgM, which can cause a cryoglobulinemic glomerulonephritis. 44 HCV infection can course with other glomerular diseases, like non-cryoglobulinemic MPGN, MN, FSGS, IgAN, and polyarteritis nodosa (PAN), and these glomerulopathies can also occur in kidney allografts. The most frequent glomerulopathies associated with chronic HBV infection are MN, MPGN, and PAN.…”

Section: Viral Glomerulopathiesmentioning

confidence: 99%

“…The most frequent glomerulopathies associated with chronic HBV infection are MN, MPGN, and PAN. 44 Advances in therapy for HCV and HBV have created opportunities for effective treatment of these patients before the kidney transplantation of patients without advanced liver disease. 45 For patients with advanced liver disease, a simultaneous kidney-liver disease can be considered.…”

Section: Viral Glomerulopathiesmentioning

confidence: 99%

“… 45 Before the direct-acting antiviral (DAA) agents, HCV was associated with lower graft and patient survival after kidney transplantation. 44 Nowadays, patients receiving hemodialysis should be treated with DAA before transplantation, and this treatment is safe for kidney transplant recipients. 44 Treatment with DAA is recommended for the treatment of patients with HCV-associated glomerulopathy, with additional treatment with immunosuppressive drugs in case of nephrotic syndrome or rapidly progressive kidney failure.…”

Section: Viral Glomerulopathiesmentioning

confidence: 99%

“… 44 Nowadays, patients receiving hemodialysis should be treated with DAA before transplantation, and this treatment is safe for kidney transplant recipients. 44 Treatment with DAA is recommended for the treatment of patients with HCV-associated glomerulopathy, with additional treatment with immunosuppressive drugs in case of nephrotic syndrome or rapidly progressive kidney failure. 2 All kidney transplant candidates with HBsAg positive should be treated before transplantation to maintain undetectable HBV DNA and avoid complications associated with the disease before transplantation.…”

Section: Viral Glomerulopathiesmentioning

confidence: 99%

See 4 more Smart Citations

Post-Transplant Glomerulonephritis: Challenges and Solutions

de Sousa

2024

IJNRD

View full text Add to dashboard Cite

Glomeruli can be damaged in several conditions after kidney transplantation, with a potential impact on the graft function and survival. Primary glomerulonephritis, a group of glomerular immunological damage that results in variable histological patterns and clinical phenotypes, can occur in kidney transplant recipients as a recurrent or de novo condition. Specific immunologic conditions associated with kidney transplantation, such as acute rejection episodes, can act as an additional trigger after transplantation, impacting the incidence of these glomerulopathies. The post-transplant GN recurrence ranges from 3% to 15%, varying according to the GN subtype and post-transplant time, mainly occurring after 3–5 years of kidney transplantation. Advances in the knowledge of glomerulonephritis pathophysiology have provided new approaches to pre-transplant risk evaluation and post-transplant monitoring. Glomeruli can be affected by several systemic viral infections, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), cytomegalovirus (CMV), and BK virus. The diagnosis of these infections, as well as the identification of possible complications associated with them, are important to minimize the negative impacts of these conditions on kidney transplant recipients’ outcomes.

show abstract

Section: Viral Glomerulopathiesmentioning

confidence: 99%

Section: Viral Glomerulopathiesmentioning

confidence: 99%

Section: Viral Glomerulopathiesmentioning

confidence: 99%

Section: Viral Glomerulopathiesmentioning

confidence: 99%

Section: Viral Glomerulopathiesmentioning

confidence: 99%

See 3 more Smart Citations

Post-Transplant Glomerulonephritis: Challenges and Solutions

de Sousa

2024

IJNRD

View full text Add to dashboard Cite

show abstract

Cytomorphological changes in urine of Sudanese patients diagnosed with hepatitis B virus

Ishaq,

Idris

2024

Preprint

View full text Add to dashboard Cite

Background: Mean AgNOR can be used to detect cytological changes in urine of patients with hepatitis B. The study aimed to detect the cytomorphological changes in urine of patients with hepatitis B in Kassala State-Sudan. This were cross-sectional descriptive study conducted in Kassala hospitals. Cytological smears of exfoliative cells were collected from urine samples by sterile containers and the obtained materials were directly applied with Pap stain and AgNOR. The data were analyzed using SPSS statistical package software version 23.0. Results: A total of 100 samples were used in this study, 50 were considered as cases and 50 as control. The urine cytological results in cases were distributed as normal in 11 (22%), suspicious of malignancy in 15 (30%), and inflammation in 24 (48%). The control group showed urine cytological results as 47 (94%) normal, and 3 (6%) inflammation. The mean AgNOR in cases was 4.76 (SD 4. 173), and in control was 0.42 (SD 0.797). The correlation between cytological results and duration of hepatitis in case group showed statistical significance (r=+0.728, p=<0.01). The correlation between cytological results and residence. The correlation between cytological results and mean AgNOR (p=0.000). Conclusions: Mean of AgNOR can be used to detect cytological changes in urine. There is strong positive correlation between mean of AgNOR and cytological results and duration of hepatitis, age and residence.

show abstract

Current perspectives of viral hepatitis

Usuda,

Kaneoka,

Ono

et al. 2024

World J Gastroenterol

View full text Add to dashboard Cite

Viral hepatitis represents a major danger to public health, and is a globally leading cause of death. The five liver-specific viruses: Hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, and hepatitis E virus, each have their own unique epidemiology, structural biology, transmission, endemic patterns, risk of liver complications, and response to antiviral therapies. There remain few options for treatment, in spite of the increasing prevalence of viral-hepatitis-caused liver disease. Furthermore, chronic viral hepatitis is a leading worldwide cause of both liver-related morbidity and mortality, even though effective treatments are available that could reduce or prevent most patients’ complications. In 2016, the World Health Organization released its plan to eliminate viral hepatitis as a public health threat by the year 2030, along with a discussion of current gaps and prospects for both regional and global eradication of viral hepatitis. Today, treatment is sufficiently able to prevent the disease from reaching advanced phases. However, future therapies must be extremely safe, and should ideally limit the period of treatment necessary. A better understanding of pathogenesis will prove beneficial in the development of potential treatment strategies targeting infections by viral hepatitis. This review aims to summarize the current state of knowledge on each type of viral hepatitis, together with major innovations.

show abstract

Management of Hepatitis C Virus and Hepatitis B Virus Infection in the Setting of Kidney Disease

Cited by 3 publications

References 141 publications

Post-Transplant Glomerulonephritis: Challenges and Solutions

Post-Transplant Glomerulonephritis: Challenges and Solutions

Cytomorphological changes in urine of Sudanese patients diagnosed with hepatitis B virus

Current perspectives of viral hepatitis

Contact Info

Product

Resources

About